• Molecular NamePrednisolone
  • SynonymDeltahydrocortisone; Methylprednisolone Acetate; PRDL; Predisolone Sodium Phosphate; Prednisolona [INN-Spanish]; Prednisolone Acetate; Prednisolone Sodium Phosphate; Prednisolone Tebutate; Prednisolonum [INN-Latin]
  • Weight360.45
  • Drugbank_IDDB00860
  • ACS_NO50-24-8
  • Show 2D model
  • LogP (experiment)1.62
  • LogP (predicted, AB/LogP v2.0)1.62
  • pkaN/A
  • LogD (pH=7, predicted)1.62
  • Solubility (experiment)0.223 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.45
  • LogSw (predicted, AB/LogsW2.0)0.22
  • Sw (mg/ml) (predicted, ACD/Labs)0.13
  • No.of HBond Donors3
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA94.83
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyThe active metabolite of prednisone.
  • Absorption_value99.0
  • Absorption (description)Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.
  • Caco_2N/A
  • Bioavailability82.0
  • Protein binding92.5
  • Volume of distribution (VD)0.44 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExcreted in the urine as either free or glucoconjugate.
  • Half life2.2 h
  • ExcretionPrednisolone is excreted via urine
  • Urinary Excretion26
  • Clerance1.0 ml/min/kg
  • ToxicityShort-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.
  • LD50 (rat)LD50=500 mg/kg
  • LD50 (mouse)N/A